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Essentials 
x Patients with abdominal aortic aneurysms (AAA) develop dense clots that are 
resistant to lysis.  
x This study explores the role of thrombin activatable fibrinolysis inhibitor (TAFI) in 
human AAA.  
x There is evidence of chronically increased TAFI activation in patients with AAA.  
x TAFI may represent a pharmacological target for cardiovascular risk reduction in 
AAA.  
 
Abstract 
Background 
Intra-luminal thrombosis is a key factor in Abdominal Aortic Aneurysms (AAA) growth. 
Patients with AAA form dense clots that are resistant to fibrinolysis. Thrombin-activatable 
fibrinolysis inhibitor (TAFI) has been shown to influence AAA development in murine models. 
Objective 
The aim of this study is to characterise the role of TAFI in human AAA. 
Methods 
Plasma levels of TAFI, TAFI activation peptide (TAFI-AP), activated/inactivated TAFI 
(TAFIa/ai) and plasmin-Į-antiplasmin complex were measured by ELISAs in patients with 
AAA (n=202) and controls (n=188).  
Results 
TAFIa/ai and TAFI-AP levels were higher in patients than controls (median (IQR): 20.3 (14.6-
32.8) vs. 14.2 (11.2-19.3) and 355.0 (232.4-528.1) vs. 248.6 (197.1-328.1) ng/ml). TAFIa/ai 
was positively correlated with TAFI-AP (r=0.164). Intact TAFI levels were not different 
between patients and controls (13.4 (11.2-16.1) vs. 12.8 (10.6-15.4) ȝJPO). Plasmin-Į-
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antiplasmin was higher in AAA patients than controls (690.0 (489.1-924.3) vs. 480.7 (392.6-
555.3) ng/ml). 
Conclusions 
The increase in TAFIa/ai and TAFI-AP suggest an increased TAFI activation in patients with 
AAA. Prospective studies are required to further elucidate the role of TAFI and fibrinolysis in 
AAA pathogenesis. 
 
Introduction 
Abdominal aortic aneurysm (AAA) is a permanent dilatation of the descending abdominal 
aorta. The aorta is described as aneurysmal when the inner-to-inner diameter is >3cm, or 
>WLPHVWKHZLGWKRIWKHµQRUPDO¶DRUWD [1]. Risk factors for AAA include smoking, 
hypertension, male gender and increasing age, with AAA disease being most common in 
men over 65 years, affecting up to 1 in 25 in this group [2]. Unlike in ischaemic heart disease 
or stroke where diabetes increases risk, diabetes is protective against AAA. The exact 
mechanism for this has not been elucidated, but may result from a number of factors, 
including increased glycation of the extracellular matrix resulting in wall stiffening, and the 
inhibition of MMP secretion in the aortic media [3]. 
The sequelae that result in AAA are unknown. At the disease end stage there is degradation 
of the tunica media, with loss of elastin, disordered collagen deposition, vascular smooth 
muscle cell apoptosis [4], infiltration of lymphocytes and macrophages [5], and 
neovascularisation [6]. Large AAA are often accompanied by the presence of intra-luminal 
thrombus (ILT) [7]. Whilst it was assumed that ILT serves to protect against rupture [8], its 
increasing size is strongly associated with both the AAA expansion rate and the risk of 
rupture [9, 10]. Aortic wall covered by ILT is thinner and has decreased tensile strength, with 
reduced elastin and smooth muscle cells [11]. ILT is constantly remodelled at the luminal 
surface, resulting in the release of proteolytic factors which contribute to the breakdown of 
the aortic wall [12]. 
The natural history of AAA is expansion with eventual rupture, which is associated with a 
mortality of up to 80% [13, 14]. There are no pharmacological treatments which can prevent 
AAA, or slow growth. Surgical intervention remains the only treatment option available, 
although this continues to carry a significant risk of morbidity and mortality.  
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Previous studies have shown that there are systemic coagulation changes in AAA. Ex-vivo, 
patients with AAA develop denser clots with smaller pores that are more resistant to lysis 
compared with controls [15]. There is evidence of increased fibrinolysis even in the early 
stages of disease, with increased levels of D-dimer, Thrombin-antithrombin complexes and 
prothrombin F1+2 [16]. Coagulation and fibrinolysis activation is maintained in patients 
undergoing endovascular repair, but not open AAA repair [17], suggesting that the presence 
of ILT, is in some way responsible for fuelling the hypercoagulability in AAA. 
 
Activated Thrombin-activatable fibrinolysis inhibitor (TAFIa), or plasma carboxypeptidase B2, 
is a metallocarboxypeptidase involved in the regulation of fibrinolysis and the maintenance of 
thrombus stability [18]. TAFI zymogen is activated by cleavage at Arg92 by thrombin, 
thrombin-thrombomodulin and plasmin, with the release of the activation peptide, TAFI-AP 
[19]. Activated TAFI (TAFIa) has a short half-life at 37ºC of 8-15 minutes, before it 
undergoes conformational change and becomes inactivated (TAFIai). TAFIai is further 
cleaved by thrombin [20] before being cleared from the circulation. TAFIa cleaves the C-
terminal lysines from partially degraded fibrin, thus removing binding sites for tPA and 
plasminogen, and reducing plasmin formation [21]. TAFIa acts via a threshold mechanism; 
once TAFIa reaches threshold level, plasmin generation is interrupted, and fibrinolysis 
essentially ceases [22]. TAFIa also possesses anti-inflammatory properties, by cleaving 
C3a, C5a, thrombin-cleaved osteopontin, and bradykinin [23-25], and therefore regulates 
inflammatory properties of thrombin.  
 
There are only two previous studies on TAFI in human AAA disease. In a small cohort study, 
Dubis et al. demonstrated decreased TAFI activity in AAA patients [26]. In another study, 
TAFIa levels were high in patients with ruptured and non-ruptured AAA, although no control 
group was included [27]. Both studies, however, were based on small sample sizes, and 
only measured TAFIa. The aim of our study was to elucidate the role of TAFI in AAA, by 
measuring plasma levels of TAFI, TAFIa/ai and TAFI-AP. 
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Materials and Methods 
Patient Recruitment 
Patients were recruited for the Leeds Aneurysm Development Study, the inclusion and 
exclusion criteria of which have been published [15]. The LEADS study is a prospective 
observational study, recruiting patients with AAA from Leeds Teaching Hospitals NHS trust. 
Control subjects were recruited via various measures, and included friends/relatives of 
patients, volunteers from surgical outpatient departments who did not have a diagnosis of 
AAA, and volunteers from the general public who were aware of the study due to media 
coverage. The inclusion criteria were presence/absence of AAA, Caucasian, age >55years, 
and the ability to provide informed consent. Exclusion criteria included the presence of any 
ongoing inflammatory, coagulatory or malignant disease, or patients taking anti-coagulant 
medication. At recruitment, in addition to collecting a blood sample, all participants had an 
abdominal ultrasound scan, which confirmed the presence (or absence) of AAA, and its size. 
They also completed a full health questionnaire, including an up to date medication history. 
A sample of free-flowing blood was collected from the antecubital vein. Blood was collected 
onto cold 0.1 M sodium citrate (9 parts of blood to 1 part of citrate), centrifuged at 4°C at 
2400g for 20 minutes, frozen in liquid nitrogen and stored at -40°C. Plasma CRP and 
creatinine levels were measured using clinical laboratory methods in the Leeds Teaching 
Hospitals Trust. 
 
TAFIa/TAFIai and PAP 
Commercially available ELISAs were used to measure plasma levels of activated and 
inactivated TAFI (TAFIa/TAFIai), and plasmin-Į-antiplasmin complexes (PAP) 
(Asserachrom® TAFIa/TAFIai, Diagnostica Stago and PAP micro ELISA, DRG®).  
 
Intact TAFI 
Intact TAFI levels were measured using ELISAs developed at KU Leuven [28]. In brief, 
Nunc-,PPXQR0D[LVRUS(/,6$SODWHV7KHUPR)LVKHU6FLHQWLILF,QFZHUHFRDWHGZLWK
ȝORI0$-7'DWDFRQFHQWUDWLRQRIȝJPOGLOXWHGLQ M phosphate buffered 
saline, PBS, pH 7.4. Plates were incubated for 72 hours at 4°C. After 72 hours, the wells 
were emptied and blocked with 300 ȝOSHUZHOORI3%6FRQWDLQLQJ%RYLQH6HUXP$OEXPLQ
(BSA). The plates were incubated for two hours at room temperature. The wells were 
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emptied, and washed four times with 300 ȝORI3%6EXIIHUFRQWDining 0.002% TWEEN®-20. 
Plasma was diluted in PTAE buffer (0.01 M PBS containing 0.002% TWEEN®-20, 0.1% 
BSA and 5 mM Ethylenediaminetetraacetic acid, EDTA). Four dilutions of 1/160, 1/320, 
1/640 and 1/1280 were prepared for each sample. Two standard samples were included on 
each plate (NPP and a single patient standard). Standard curves were created using purified 
TAFI, with serial dilutions in the range of 3.125-100 ng/ml. On all plates, equal numbers of 
samples from patients with AAA and control subjects were included, with 180 ȝORIVDPSOH
added to each well. Plates were incubated overnight at 4°C. After washing, 170 ȝORI
secondary antibody (MA-T30E5A2-HRP, diluted 1/8000 in PTA buffer (0.01 M PBS 
containing 0.1% BSA and 0.002% TWEEN®-20), was added, plates were incubated for 2 
hours at room temperature, emptied and washed.  To produce a colorimetric reaction, 160 ȝO
of a substrate solution containing o-Phenylenediamine (OPD) was added to each well. The 
reaction was stopped using 50 ȝORI M H2SO4 and the absorbance was measured at 492 
nm OD.  
 
TAFI AP  
TAFI-AP levels were measured using ELISAs developed at KU Leuven [28]. For this ELISA, 
plates were coated, and blocked as described above. To produce the TAFI-AP standard, 
purified TAFI (final concentration 3.75 ȝg/ml) was incubated along with calcium (final 
concentration 5 mM), thrombin, (final concentration 16 nM) and thrombomodulin (final 
concentration 15 nM), in a water bath at 37°C for exactly 13 minutes. The dilution buffer 
contained 25 mM HEPES, 137 mM NaCl, 3.5 mM KCl, 3 mM CaCl2 and 0.1% BSA, pH 7.4. 
After 13 minutes, D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK) was 
added to a final concentration of 30 ȝ0$VWDQGDUGFXUYHZDVSURGXFHGXVLQJ-20 ng/ml 
of this TAFI-AP. Plasma samples were diluted at 1/40, 1/80, 1/160 and 1/320. The 
secondary antibody for this ELISA was MA-T18A8-HRP, which was diluted as described 
above. OPD was used to produce the colorimetric reaction. 
 
Fibrinogen Levels 
Fibrinogen levels were determined using the Clauss method with a Start 4 Heamostasis 
analyzer (Diagnostica Stago,) and the Fibri-prest automated kit (Diagnostica Stago) 
according to the manufacturer's instructions. 
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Sample size and Statistical Analysis 
Samples sizes were determined using pilot data. For the intact TAFI ELISA, with a standard 
deviation in each group of 4 ȝJPOZLWKSRZHUDWSSHUJURXSZHUHUHTXLUHGWR
detect a significant difference in the mean values. As the variation was higher in the pilot 
data for the TAFIa/TAFIai (standard deviation up to 19 ng/ml) and TAFI-AP ELISAs 
(standard deviation up to 250 ng/ml), 105 and 163 samples respectively were required per 
group. Normality of data distribution was tested using Shapiro-Wilk. A normal distribution 
could not be achieved by transforming data using Log10 or natural Log for the results of TAFI 
plasma levels, and so data was analysed as non-parametric data. Non-parametric data was 
analysed using Mann-Whitney U, and parametric data was analysed using Student¶V t-
testing. Non-parametric data is presented as median (Inter-quartile range), and parametric 
data as mean±standard deviation. For patient demographics, continuous data is presented 
as median (Inter-quartile range) and categorical data as number of subjects (% of total), with 
differences between groups analysed using T-test for continuous data and Pearsons Chi-
Squared for categorical data.  
 
Given the heterogeneous and complex nature of AAA, it was likely that a number of 
confounding factors would be present. As a result, any differences in plasma levels between 
groups were adjusted for confounders using multivariate analysis. Factors included in the 
models were age, aspirin and statin use, history of MI, BP, smoking status, gender, 
fibrinogen concentration and CRP.  
 
Results 
In total, 202 AAA patients and 188 control subjects were included in this study. Their basic 
demographics are shown in Table 1. The two groups were compared for compounding risk 
factors, such as cardiovascular disease and smoking. As expected, there were some 
marked differences in the incidence of myocardial infarction (AAA 27.7 vs. controls 6.4%, 
p<0.0001), hypertension (61.9 vs. 31.6%, p<0.0001) and smoking (ever smoked, 89.6 vs. 
67.0%, p<0.0001), which remained even after correcting for multiple testing (Benjamini and 
Hochberg). Patients with AAA were further classified into large AAA (>5 cm) and small AAA 
(3-5 cm). The demographics for these groups are included in Table 1.  
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The levels of intact TAFI were comparable between groups; AAA 13.36 (11.21-16.12) vs. 
controls 12.76 (10.62-15.35) ȝJPO0DQQ:KLWQH\8WHVWS , Figure 1A. There was no 
difference with size of AAA; large AAA 13.27 (11.24-15.53) vs. small AAA 13.56 (11.04-
16.98) ȝJPO7KHUHZDVDQLQFUHDVHLQWKHSODVPDOHYHOVRI7$),D7$),DLPHDVXUHGLQAAA 
patients compared with controls (AAA 20.32 (14.57-32.79) vs. controls 14.19 (11.20-19.25) 
ng/ml, Mann Whitney U test p<0.0001), and this effect was correlated with increasing size of 
AAA (Small AAA 18.72 (13.63-30.38), Large AAA 21.55 (14.80-36.50) ng/ml, Kruskal Wallis 
controls/small AAA/large AAA p<0.0001), Figure 1B and 1E. The same was true for plasma 
levels of TAFI-AP; AAA 355.0 (232.4-528.1) vs. controls 248.6 (197.1-328.1) ng/ml, Mann 
Whitney U test p<0.0001, Figure 1C. The differences between patients and controls in 
TAFIa/TAFIai and TAFI AP levels remained significant after adjusting for confounding factors 
in a multivariate model (p=0.03 and p=0.001 respectively).  
 
Plasma levels of TAFIa/TAFIai and TAFI-AP showed a positive correlation (r=0.164, 
p=0.001), indicating that the results of these ELISAs are both indicators of the amount of 
TAFI that has been activated (Figure 1D). Plasma levels of TAFIa/ai were divided into 
quartiles (1st <12.49, 2nd 12.5-17.05, 3rd 17.06-26.26, 4th >26.26 ng/ml) in order to establish if 
a dose effect was present for TAFIa/ai and AAA. As TAFIa/ai levels increased, the 
percentage of subjects in each set with AAA increased (30.9, 44.3, 59.8 and 72.4% 
respectively), Figure 1F. Plasmin-Į-antiplasmin complex levels were also significantly 
increased in patients with AAA (AAA 690.0 (489.1-924.3) vs. controls 480.7 (392.6-555.3) 
ng/ml p<0.0001), Figure 2, indicating a possible role for plasmin in TAFI activation in AAA. 
 
Previous work from our group has shown that there was no difference in the distribution of 
the Thr325Ile polymorphism between AAA patients and controls [30]. Despite this, levels of 
TAFIa/ai and TAFI-AP still correlated with genotype across the whole population, with a 
reduction in TAFIa/ai and TAFI-AP in Ile/Ile homozygotes (Figure 3). 
 
Discussion  
We investigated aspects of TAFI pathophysiology in a large group of patients with AAA and 
compared these with a control population. While TAFI total antigen levels were similar 
between patients and controls, TAFI activation peptide and TAFIa/TAFIai were both 
increased in AAA patients compared with controls. These data indicate increased activation 
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of TAFI in-vivo in AAA patients, and these changes correlated with AAA size. PAP levels 
were higher in patients versus controls, suggesting an increased activation of TAFI by 
plasmin in AAA patients, and that TAFI activation represents a marker of inflammation and 
coagulation in these patients. Future prospective studies are warranted to further investigate 
the importance of TAFI in AAA formation and development. 
 
TAFI levels in the plasma of patients with AAA were studied using a number of different 
ELISA systems. Historically, there has been some difficulty in measuring TAFI using ELISAs, 
as a number of antibodies were specific only for one of two alleles of the Thr325Ile 
polymorphisms [19]. In addition, the difference in half-life between the two forms of TAFI 
may have led to falsely high or low results in patients who are homozygous for either form of 
TAFI. The ELISAs used for this study were not specific for either isoform, and detect both 
forms with equal specificity. Although the half-life of the two TAFIa forms is different, by 
measuring TAFIa/TAFIai in combination, any TAFIa already inactivated in the sample should 
have still been detected in equal measure, thus correcting for the difference in half-life 
between the two forms. Furthermore, we previously investigated TAFI Thr325Ile in patients 
with AAA and found no difference in genotype distribution of this polymorphism in patients 
and controls [29]. 
 
Whilst there was no difference between the levels of TAFI zymogen between patients with 
AAA and controls, the levels of TAFIa/TAFIai and the TAFI activation peptide were 
significantly higher in patients compared with control subjects, indicating increased TAFI 
activation in AAA. AAA is a chronic disease, and this increased TAFI activation could be due 
to the continuous plasmin generation within the ILT and the aortic wall [30], or caused by the 
increased thrombin generation previously observed in AAA [16,17]. It would have been 
interesting to be able to correlate TAFI levels with ILT itself. In our study, all patients 
underwent abdominal ultrasound scanning, the resolution of which can make it difficult to 
accurately quantify ILT. Further studies with magnetic resonance imaging or similar would be 
able to explore the association between activated TAFI and ILT in more detail.  
 
Only a fraction of the TAFI zymogen needs to be activated to have a full effect (in the order 
of 1%),[22] and so only in the case of massive TAFI consumption would there be a 
detectable decrease in the total zymogen levels, which was not seen in our cohort.  The 
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relative increase in activation of TAFI results in higher levels of TAFIa/TAFIai and the TAFI-
AP. Although the TAFIa/TAFIai ELISA aims to measure both active and inactive TAFI in the 
plasma samples, it is likely that due to the very short half-life of active TAFI, the majority of 
what is measured by this ELISA is actually inactivated TAFI.  
 
While the thrombin/thrombomodulin complex is generally considered to be the main 
physiological activator of TAFI, plasmin has been shown to also be capable of activating 
TAFI both in vitro and in vivo [31]. Certain anionic molecules, including dermatan sulphates 
and polyphosphates, have been shown to enhance plasmin-mediated activation of TAFI [32]. 
Polyphosphates are released by activated platelets [33], and in view of the increased 
prothrombotic activity in AAA [17], plasma concentrations of polyphosphates are likely 
increased in AAA patients. Alongside the higher PAP levels, this seems to suggest that in 
patients with AAA, plasmin-mediated TAFI activation may play an important role. It is known 
that the levels of D-dimer (the plasmin mediated fibrin breakdown product) are higher in 
patients with AAA compared with control subjects [16,17]. Also, high levels of D-dimer and 
plasmin-antiplasmin complexes have been shown within the ILT of patients with AAA [34]. 
However, increased thrombin generation through increased levels of F1+2 and TAT have 
also been demonstrated in AAA [16,17], and could therefore also contribute to increased 
TAFI activation. Further studies are needed to investigate whether TAFI activation in AAA is 
due to increased plasmin or thrombin generation. 
 
This study has several limitations. The control group was not matched with the patient group 
for age and gender. However, since TAFI correlates with age only in women and not in men 
[35] and our study consisted largely of men, this unlikely influences the results in our current 
study. There were differences between the AAA and the control groups in terms of past 
medical history, the majority of which are known to be associated with AAA disease. Whilst it 
is impossible to correct for all possible confounding factors, even when correcting for many 
(including age, gender, past medical history of MI, aspirin, statin, smoking status), the 
significant differences in the levels of TAFIa/ai and TAFI-AP remained. Finally, we analysed 
TAFI using different in-house assays, each measuring a different aspect of TAFI biology. 
Using different assays may provide differing results, but ultimately provide a more 
comprehensive picture of the changes occurring to TAFI in AAA. Plasma samples were not 
taken in the presence of a stabilizer that could stabilize TAFIa activity which would allow 
measurement of TAFIa activity. We did not include an assay that measures TAFIa activity. 
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In conclusion, we observed evidence of altered in-vivo TAFI activation in patients with AAA, 
as shown by the increased plasma levels of TAFIa/TAFIai and TAFI-AP. Together, these 
data indicate a possible role for TAFI in AAA formation and progress, and warrant 
prospective studies to investigate this further.  
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Table 1. Demographics of patients and control subjects 
 
Figure 1. Plasma levels of TAFIa/TAFIai and TAFI-AP are increased in patients with 
AAA, and are associated with aneurysm size 
 
Figure 2. Plasma levels of PAP are increased in patients with AAA. 
 
Figure 3. Impact of TAFI Thr325Ile polymorphism on TAFIa/ai and AP levels. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Table 1. Demographics of patients and control subjects 
 
 Controls (no AAA) 
n=188 
Patients (AAA) 
n=202 
Large AAA (>5cm) 
n=110 
Small AAA (3-5cm) 
n=92 
p-value 
AAA vs. 
controls 
Aorta size (mm) 1.8 (1.6-2.0) 5.2 (4.0-6.3) 6.3 (5.7-7.0) 4.0 (3.5-4.5) <0.0001 
Age (years) 69.0 (64.0-75.8) 74.0 (68.0-80.0) 75.0 (68.0-80.9) 73.0 (68.0-79.0) <0.0001 
Male n(%) 132 (70.2%) 169 (83.7%) 92 (88.5%) 77 (78.6%) 0.002 
BMI (weight kg/height m2) 27.8 (24.7-30.2) 27.4 (24.2-30.6) 27.4 (23.9-30.5) 27.4 (24.9-30.7) 0.68 
Drug history n(%) Aspirin 64 (34%) 145 (71.8%) 73 (70.2%) 72 (73.5%) <0.0001 
Statin  84 (44.7%) 168 (83.2%) 86 (82.7%) 82 (83.7%) <0.0001 
Past Medical 
History 
n(%) 
DM 21 (11.2%) 26 (12.9%) 13 (12.5%) 13 (13.3%) 0.432 
MI 12 (6.4%) 56 (27.7%) 31 (29.8%) 25 (25.5%) <0.0001 
Angina 17 (9.0%) 51 (25.2%) 34 (32.7%) 17 (17.3%) <0.0001 
CVA/TIA 25 (13.3%) 27 (13.4%) 13 (12.5%) 14 (14.3%) 0.552 
Ĺ%3 67 (35.6%) 125 (61.9%) 55 (52.9%) 70 (71.4%) <0.0001 
Smoking Status 
n(%) 
Current 22 (11.7%) 45 (23.9%) 25 (24.0%) 20 (20.4%) 0.012 
Ever 126 (67.0%) 181 (89.6%) 96 (92.3%) 85 (86.7%) <0.0001 
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Plasma Fibrinogen (g/L)  3.4 (3.1-4.0) 3.8 (3.3-4.5) - - <0.0001 
C-reactive protein (ng/ml) <5 (<5-5) <5 (<5-9.5) - - 0.0002 
Creatinine ȝPRO/ 87 (77-103) 101.5 (89-116.3) - - <0.0001 
 
DM ± Diabetes Mellitus, MI ± 0\RFDUGLDO,QIDUFWLRQ&9$7,$&HUHEURYDVFXODU$FFLGHQWRU7UDQVLHQW,VFKDHPLF$WWDFNĹ%3± hypertension, 
AAA ± abdominal aortic aneurysm, BMI ± body mass index. Results are shown as median (interquartile range) for continuous data and number 
(percentage of patients) for discrete data. Differences between groups were analysed using *Pearsons Chi squared and #Mann Whitney U 
Test, with p <0.05 taken as being statistically significant after correcting for multiple testing.  
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Figure 1. Plasma levels of TAFIa/TAFIai and TAFI-AP are increased in patients with 
AAA, and are associated with aneurysm size. Levels of TAFI, TAFIa/TAFIai and TAFI-AP 
were measured in the plasma of patients with AAA (n=202) and control subjects (n=188) 
using ELISAs. There was no difference in the plasma levels of total TAFI zymogen in 
patients with AAA compared with controls (Mann Whitney U Test, p=0.13, Panel A). The 
levels of TAFIa/TAFIai and TAFI-AP were significantly increased in patients with AAA 
compared with control subjects; TAFIa/TAFIai Mann Whitney U Test p<0.0001, Panel B, and 
TAFI-AP Mann Whitney U Test p<0.0001, Panel C. Plasma levels of TAFIa/TAFIai and 
TAFI-AP are positively correlated, Panel D. The increase in plasma TAFIa/TAFIai levels are 
associated with AAA size, Panel E, Kruskal Wallis p<0.0001. The percentage of patients 
with AAA increases with levels of TAFIa/ai expressed as quartiles, Panel F. 
 
 
 
 
 
 
 
Figure 2. Plasma levels of PAP are increased in patients with AAA. Plasma levels of 
plasmin-Į-antiplasmin complexes (PAP) were measured in the plasma of patients and 
controls using an ELISA. Plasma levels were higher in patients compared with controls (AAA 
690.0(489.1-924.3) vs. Controls 480.7(392.6-555.3) ng/ml p<0.0001). 
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Figure 3. Impact of TAFI Thr325Ile polymorphism on TAFIa/ai and AP levels. 
Levels of TAFIa/ai (panel A) and TAFI-AP (panel B) were correlated with Thr325Ile 
polymorphism status across all participants (AAA and controls). Plasma levels of 
both TAFIa/ai and TAFI-AP were lower in participants who were homozygote for the 
isoleucine allele. Results are displayed as median (IQR), analysed using Mann 
Whitney-U test, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 vs Thr/Thr 
homozygotes.  
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